ClinicalTrials.Veeva

Menu

Short-pulse Subthreshold vs Infrared Micropulse for Diabetic Macular Edema

M

Moorfields Eye Hospital Centre Abu Dhabi

Status

Completed

Conditions

Diabetic Macular Edema

Treatments

Procedure: Macular Laser

Study type

Interventional

Funder types

Other

Identifiers

NCT04505306
Moorfields Eye Abu Dhabi

Details and patient eligibility

About

When applied according to manufacturer recommendations, short-pulse system may yield more temporary reduction in edema while infrared micropulse system may yield slightly better functional outcomes.

Full description

Purpose: To assess both anatomic and functional outcomes between short-pulse continuous wavelength and infrared micropulse lasers in the treatment of DME.

Materials and Methods: A prospective interventional study from tertiary care eye hospital - King Khaled Eye Specialist Hospital (Riyadh, Saudi Arabia). Patients with center-involving diabetic macular edema were treated with subthreshold laser therapy. Patients in the micropulse group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA). Laser was applied according to manufacturer recommendations for MicroPulseTM in a confluent mode (low intensity/high density) to the entire area of the macular edema. Patients in the short-pulse group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn. Main outcome measures included best-corrected visual acuity (BCVA) and foveal thickness at baseline and the last follow-up visit.

Enrollment

113 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • center-involving clinically significant macular edema due to diabetic retinopathy (>300 microns)
  • clear ocular media
  • ETDRS visual acuity >29 letters (Snellen equivalent of 20/150) or better
  • treatment naïve eyes or previously treated with antiangiogenic intravitreal agent(s) more than 6 months ago to allow for long wash-out period

Exclusion criteria

  • non-center involving diabetic macular edema
  • previous retinal laser or surgery
  • intravitreal steroid use
  • any condition that may be associated with a risk of macular edema such as age-related macular degeneration, retinal vein occlusion, vitreomacular traction, epiretinal membrane and others.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

113 participants in 3 patient groups

Subthreshold Laser 30%
Active Comparator group
Description:
Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 30% EndPoint algorithm.
Treatment:
Procedure: Macular Laser
Subtreshold Laser 50%
Active Comparator group
Description:
Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 50% EndPoint algorithm.
Treatment:
Procedure: Macular Laser
Micropulse Laser
Active Comparator group
Description:
Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle.
Treatment:
Procedure: Macular Laser

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems